The pharma giant will pay more than $346 million to settle charges that it bribed doctors to prescribe their drugs.
The deal gives the Swiss drugmaker a neurological disease treatment that may have "a multi-billion dollar peak sales potential."
The acquisition of Novartis' stake will give GSK full control over the revenues from such products as Sensodyne toothpaste and the Excedrin pain reliever.
The rate of spending increase on high-tech pharmaceuticals will top 17% for a second consecutive year, a study says.
The Swiss drug maker allegedly turned specialty pharmacies into a "biased sales force" for its medications.
Meryl Zausner, the U.S. finance chief of Novartis, shares her thoughts on the CFO role and the path she took to get there.
How are women making it to the top in finance? Sometimes by making unconventional, even risky, career moves.
